Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Alphamab Forms $615.5 Million Drug Development Pact with ArriVent

publication date: Jun 6, 2024

Suzhou Alphamab Oncology announced a deal with ArriVent BioPharma, a Philadelphia area biotech, to use its linker-payload (Alphatecan) and glycan-conjugation platforms to discover antibody drug conjugates for ArriVent. Alphamab will receive an unspecified upfront payment and potential milestones of up to $615.5 million, plus royalties. Jiangsu Alphamab BioPharma, an Alphamab Oncology subsidiary, will retain Greater China rights to the ADC products. Founded in 2008, Alphamab is currently advancing more than 30 active projects, including biosimilars, novel mAbs and engineered version of mAbs and proteins. More details....

Stock Symbols: (HK: 9966) (NSDQ: AVBP)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital